CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
Intellia data spark debate about CRISPR drug’s potential
Newly published data show the therapy reduced the rate of swelling attacks in people with hereditary angioedema, but didn't ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
FierceBiotech3h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
technologynetworks16h
CRISPR-Cas9 Therapy Shows Promise As Single-Dose Treatment for Hereditary Angioedema
A single treatment with, a CRISPR-Cas9-based gene editing therapy, is enough to replace the daily medication of patients with ...
EurekAlert!4h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
RNA editing: emerging from CRISPR’s shadow
Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...
Armed robbery in Revesby4h
CRISPR-Cas9 Phase 2 Boosts Hereditary Angioedema Hope
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with ...
Researchers develop new tool to predict the impact of genetic variants
A study published in the journal Cell Genomics introduces a new tool called FUSE (Functional Substitution Estimation) that ...
Medindia7d
CRISPR Gene Editing Technology
CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...
BioPharma Dive2d
Editas, changing course again, looks to partner lead CRISPR therapy
The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...
GEN1d
“Give Cas a Chance”: Fyodor Urnov Says He Wants a CRISPR Revolution
An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.